We bring high-value technologies designed to solve critical, analytical problems. We enable profound discoveries, optimize lab operations and ensure regulatory compliance. We help customers turn global industry challenges into the medicines that offer hope.
As drug safety regulations intensify, manufacturers must ensure their formulations, like polysorbate 80, are free from visible particles and contain a limited number of subvisible particles larger than 10 µm (per FDA requirements). These particulates aren’t just due to process instability but also the degradation of formulation excipients. Mechanical stress during manufacturing can cause protein…
In the fight against COVID-19, one technology has quietly transformed the way we combat this deadly virus—lipid nanoparticles (LNPs). These tiny vesicles serve as an ideal vehicle for genetic material, encapsulating and ferrying it directly into our cells. They act as a shield for mRNA, protecting it from degradation in the body while ensuring its…
Our goal is to create new value through the expanded global reach and combination of Waters and Wyatt technology. The delivery of these two pieces along with our deep scientific expertise, will support our customers to make life-changing therapies more accessible.
Did you know that subvisible particles (SVPs) are the leading cause of drug product recalls? Despite being tiny, these subvisible particles have a big impact on biologic, cell, and gene therapies – not only limiting a product’s shelf life but also comprising patient safety. For this reason, injectable drugs face strict requirements to be virtually free of…
We believe we have created the most intuitively simple HPLC we have ever made. It is the first-ever system dedicated to the specific needs of the QC lab, and it will save our customers time, money, and stress.
An increased emphasis on new technology and innovation for pharmaceutical companies is contributing to the supply of more consistent quality and safer products for patients.
During a Waters-hosted roundtable discussion on the risk and cost associated with human errors in pharma quality control (QC) laboratories, key opinion leaders in the industry shared expert insights.
What does smart tech look like in an analytical lab today? Labs that are primed and ready to take advantage of future technological advances will get ahead of their competitors. How will a lab get there?
For contract organizations working in the pharmaceutical industry, operating at peak performance and capacity is a vital step towards delivering life-saving therapies.
Solving analytical challenges is at the core of our DNA and when it comes to oligonucleotide analysis, we’re at a point now where we can bring together the many advancements we’ve made across the analytical value stream into complete end-to-end workflows that truly deliver best-in-class analytical performance and productivity.
Healthcare Providers and medical device manufacturers alike are working diligently to ensure that their services and products are compliant with these new regulations in the medical device industry in the European Union (EU).
Waters has been progressing intact mass analyses for an equally long time. Development of the new waters_connect INTACT Mass app was a user-centric process.